Overview
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
Status:
Completed
Completed
Trial end date:
2008-10-01
2008-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This trial is conducted in Europe. The aim of this trial is to obtain the PTPN11 mutation status and investigate the impact of the PTPN11 mutation status on the effect of somatropin (Norditropin®) by use of data obtained in the GHNOO-1658 trial.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:- Participation in the GHNOO-1658 trial
- Subject has completed genetic testing of PTPN11 mutation